Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OptiBiotix has human studies showing clinically meaningful reductions in hunger, improved gut microbiome composition, and improvements in metabolic markers such as cholesterol and blood sugar for its flagship products (e.g., SlimBiome®, WellBiome®, SweetBiotix®). Products are sold globally, often in partnership with international brands, and a pipeline of next-generation microbiome modulators is nearing commercialization[5][1].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OptiBiotix Health.